Anti-OX40/CpG treatment, but not anti-PD-L1 treatment, increased the CD431B11+CD8+ T cell subset on day 13 post tumor challenge (6 days after the start of the anti-OX40/CpG treatment), while at later time points these treatments resulted in a comparable increase compared with untreated mice. This evidence concerns the gene CD8A and neoplasm.